NEW YORK (GenomeWeb) – Goldman Sachs today initiated coverage of Exact Sciences with a Buy rating, calling the company's colorectal cancer screening test "the best new product cycle in our coverage."

In a report, analyst Isaac Ro gave Exact Sciences' shares a six-month price target of $19 and noted three catalysts to the molecular diagnostic firm's stock — US Food and Drug Administration approval and Centers for Medicare and Medicaid Services reimbursement; a concentrated sales channel that is undervalued; and an undemanding valuation on the company's shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.